PHAR stock fell 2.78 percent as earnings shape the outlook

Published on 10/08/2026 at 00:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PHAR stock was last quoted at EGP 113.99 on October 5, down 2.78 percent. EIPICO's latest quarter brought EGP 2.52 billion in sales and EGP 342.25 million in net income.

PHAR, EGS38081C013, Illustration mit AI erstellt.

PHAR stock was last quoted at EGP 113.99 on the Egyptian Exchange on October 5, 2026, down 2.78 percent from the prior close. The latest quarterly figures put revenue and profitability ahead of the next market debate.

Quarterly sales reached EGP 2.52 billion

Investing.com identifies August 31, 2026, as the latest release date and reports EGP 2.52 billion in sales, EGP 342.25 million in net income and EPS of EGP 2.03 for the latest quarter. The figures relate to the second quarter and six months ended June 30, 2026, as listed by MarketScreener.

Quarterly revenue moved from EGP 2.53283 billion in the previous quarter to EGP 2.52089 billion in the latest quarter, a decline of EGP 12.0 million. Net income increased from EGP 283.95 million to EGP 342.25 million over the same comparison, a gain of EGP 58.30 million, according to Investing.com.

Two analysts set a Neutral view

The analyst picture is restrained. Investing.com shows a Neutral consensus from two analysts, with an average 12-month price target of EGP 108.20. That target is 5.08 percent below the October 5 price of EGP 113.99, making the latest quotation higher than the published average target.

The same summary lists an annualized payout of EGP 3.50 and a dividend yield of 3.24 percent. Those figures add an income component to the earnings profile, while the 165.08 percent debt-to-equity ratio highlights the balance-sheet factor alongside operating profit.

Exports remain central to EIPICO

EIPICO describes a portfolio of more than 400 products, 117 pipeline projects and 5,000 employees across 25 therapeutic classes. Its website also says the company exports to 78 countries and holds a 26 percent share of Egypt's pharmaceutical exports by value.

MarketScreener reported that PHAR joined the S&P Global BMI and S&P Pan Arab Composite on September 21, 2026. The index additions broaden the stock's benchmark visibility, but the EGP 108.20 average target remains the clearest quantified counterpoint to the October quotation.

PHAR stock stays above the average target

PHAR stock was last quoted at EGP 113.99 on the Egyptian Exchange on October 5, 2026. The next investor checkpoint is the balance between EIPICO's EGP 342.25 million quarterly net income, export reach and the Neutral analyst average of EGP 108.20.